SLC18A2 and type 2 diabetes mellitus: In 2016, a new clinical trial was carried out to further study the PET imaging of the pancreatic [18F]FP-(+)-DTBZ uptake and binding to assess VMAT2 as a biomarker of BCM in a relatively larger cohort, which included 14 healthy controls, 8 patients with T1D and 3 patients with Type 2 Diabetes (T2D) [17].